Nektar Therapeutics (NASDAQ:NKTR) does about 2.70M shares in volume on a normal day but saw 1432790 shares change hands in Tuesday trading. The company now has a market cap of 215.30M USD. Its current market price is $1.17, marking a decrease of -4.10% compared to the previous close of $1.22. The 52 week high reached by this stock is $1.93 whilst the lowest price level in 52 weeks is $0.41.
Nektar Therapeutics (NKTR) has a 20-day trading average at $1.2150 and the current price is -39.32% off the 52-week high compared with 183.57% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.4257 and its 200-day simple moving average is $0.8617. If we look at the stock’s price movements over the week, volatility stands at 13.54%, which decreases to 10.63% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 43.36 to suggest the stock is neutral.
The consensus objective for the share price is $1.80, suggesting that the stock has a potential upside of 35.0% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 28, 2024 when Rodman & Renshaw initiated the stock to “Buy” and issued a price target of $2.
Nektar Therapeutics (NKTR) stock is up 9.35% over the week and -7.87% over the past month. Its price is 107.08% year-to-date and 103.41% over the past year.
To reach the target analysts have set, the stock logically needs to grow 35.0 percent from here.
The company has a return on investment of -51.83% and return on equity of -95.68%. The beta has a value of 0.67. Price to book ratio is 1.70 and price to sales ratio is 2.39.
